Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms- |
Target |
Action antagonists |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | United States | 04 Apr 2023 | |
Kidney Neoplasms | Preclinical | United States | 04 Apr 2023 | |
Ovarian Cancer | Preclinical | United States | 04 Apr 2023 | |
Prostatic Cancer | Preclinical | United States | 04 Apr 2023 |